Cellebrite DI Ltd.

How big is Cellebrite DI Ltd.?

As of Jun 18, Cellebrite DI Ltd. has a market capitalization of 3,827.40 million, with net sales of 419.17 million and a net profit of -194.23 million over the latest four quarters. The company reported shareholder's funds of 336.02 million and total assets of 696.57 million as of Dec 24.

Market Cap: As of Jun 18, Cellebrite DI Ltd. has a market capitalization of 3,827.40 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Cellebrite DI Ltd. reported net sales of 419.17 million and a net profit of -194.23 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 336.02 million and total assets of 696.57 million.

What does Cellebrite DI Ltd. do?

Cellebrite DI Ltd. is a small-cap software company with recent net sales of $108 million and a net profit of $17 million. It has a market cap of $3.83 billion, but is currently loss-making with a P/E ratio of NA and no dividend yield.

Overview: Cellebrite DI Ltd. operates in the software products industry and is classified as a small-cap company.<BR><BR>Financial Snapshot: Most recent Net Sales: 108 Million (Quarterly Results - Mar 2025). Most recent Net Profit: 17 Million (Quarterly Results - Mar 2025). Market-cap: USD 3,827.40 Million (Small Cap).<BR><BR>Key Metrics: P/E: NA (Loss Making). Industry P/E: NA. Dividend Yield: 0.00%. Debt Equity: -1.11. Return on Equity: -53.38%. Price to Book: 10.53.<BR><BR>Contact Details: No Company Details Available. Registrar Address: Not available.

Should I buy, sell or hold Cellebrite DI Ltd.?

Is Cellebrite DI Ltd. technically bullish or bearish?

As of October 3, 2025, Cellebrite DI Ltd. shows a neutral technical trend with mixed signals, being mildly bullish on weekly indicators but mildly bearish on monthly ones, while underperforming the S&P 500 year-to-date but significantly outperforming it over the last three years.

As of 3 October 2025, the technical trend for Cellebrite DI Ltd. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD and KST are mildly bullish, while the monthly MACD and KST are mildly bearish. The Bollinger Bands indicate a mildly bullish trend on the weekly and bullish on the monthly, while the daily moving averages show a mildly bearish stance. The stock has underperformed the S&P 500 year-to-date, with a return of -14.68% compared to the S&P 500's 14.18%, but has outperformed over the last three years with a return of 317.67% versus 82.57%.

Is Cellebrite DI Ltd. overvalued or undervalued?

As of November 14, 2025, Cellebrite DI Ltd. has an attractive valuation grade, indicating it may be undervalued with a Price to Book Value of 10.89 and an EV to EBITDA ratio of 50.27, despite its loss-making status, especially when compared to peers like Clearwater Analytics and SolarWinds.

As of 14 November 2025, the valuation grade for Cellebrite DI Ltd. moved from fair to attractive, indicating a more favorable outlook for the company. Based on the available metrics, Cellebrite appears to be undervalued, particularly given its Price to Book Value of 10.89 and an EV to EBITDA ratio of 50.27, which, while high, suggests potential growth relative to its current valuation. The EV to Sales ratio stands at 8.48, further supporting the notion that the company may be undervalued compared to its peers.<BR><BR>In comparison to its industry, Cellebrite's P/E ratio is not applicable due to its loss-making status, but it is noteworthy that Clearwater Analytics Holdings, Inc. has a P/E of 12.49, while SolarWinds Corp. shows a P/E of 25.03, highlighting the disparity in valuation among peers. Although specific return data for Cellebrite is not available, the overall market sentiment reflected in the S&P 500 suggests that the stock's recent performance could align with a positive valuation narrative.